Skip to Content
Morningstar

Lonza Group Ltd LONN

Morningstar Rating
Unlock
Stock XSWX Rating as of
CHF 510.20 −12.20 (2.34%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Price vs Fair Value

View History
LONN is trading at a 4% discount.
Price
CHF 510.20
Fair Value
CHF 768.00
Uncertainty
Medium
1-Star Price
CHF 815.70
5-Star Price
CHF 992.00
Economic Moat
Ffbtgn
Capital Allocation
Cmybdphvb

Bulls Say, Bears Say

Bulls

The pharma biotech and nutrition segment is a sticky business with long-term contracts and high switching costs for its customers.

Bears

Lonza is vulnerable to facility closures whether from natural disasters or manufacturing issues, as a warning letter from the FDA can result in manufacturing delays or closures.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LONN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
CHF 522.40
Day Range
CHF 505.80–516.80
52-Week Range
CHF 308.60–599.40
Bid/Ask
CHF 0.00 / CHF 0.00
Market Cap
CHF 36.79 Bil
Volume/Avg
323,530 / 218,058

Key Statistics

Price/Earnings (Normalized)
31.81
Price/Sales
5.60
Dividend Yield (Trailing)
0.69%
Dividend Yield (Forward)
0.78%
Total Yield
3.43%

Company Profile

Lonza Group ltd is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Large Growth
Total Number of Employees
18,000
Website
https://www.lonza.com

Competitors

Valuation

View More
Metric
LONN
02269
ICLR
Price/Earnings (Normalized)
 31.819.8021.23
Price/Book Value
 3.891.272.61
Price/Sales
 5.603.052.97
Price/Cash Flow
 28.247.6918.93
Price/Earnings
LONN
02269
ICLR

Financial Strength

Metric
LONN
02269
ICLR
Quick Ratio
 1.121.791.16
Current Ratio
 1.772.201.21
Interest Coverage
 9.0040.972.99
Quick Ratio
LONN
02269
ICLR

Profitability

Metric
LONN
02269
ICLR
Return on Assets (Normalized)
 5.28%9.91%6.18%
Return on Equity (Normalized)
 9.02%14.09%11.98%
Return on Invested Capital (Normalized)
 7.29%11.82%10.27%
Return on Assets
LONN
02269
ICLR
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Diagnostics & Research Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncYcgrpsxpcLbcxk$208.9 Bil
DHR
Danaher CorpJglxvnzghWywlrk$177.3 Bil
IQV
IQVIA Holdings IncBgnhzzhgwMzzjmh$41.4 Bil
IDXX
IDEXX Laboratories IncDmbhnmwlscDcvtyb$39.7 Bil
A
Agilent Technologies IncWyfnyxlcTjvz$39.4 Bil
MTD
Mettler-Toledo International IncLmphqxjsxBjgxbcv$25.6 Bil
ICLR
Icon PLCWthnvwfnwThqtwv$24.1 Bil
ILMN
Illumina IncQgvjfxfwJnvwgm$18.8 Bil
WAT
Waters CorpJnbztxmzksFxcvk$18.0 Bil
LH
Laboratory Corp of America HoldingsZtwdfqwdrSwvzlhl$16.8 Bil

Sponsor Center